Featured News

Our Partners

Latest News

Blood Cancer Awareness Month 2026: 15 Organizations Advancing Blood Cancer Innovation Across the Mid-Atlantic and North Carolina

September is recognized in the U.S. as Blood Cancer Awareness Month, a period dedicated to increasing awareness of leukemia, lymphoma, myeloma and the broader family of blood cancers, while highlighting research, patient support and the people working toward better treatments. The observance traces back to a 2010 U.S. House resolution recognizing September 2010 as Blood […]

Reckitt Doubles Its Investment in North Carolina’s Largest OTC Manufacturing Facility

Reckitt has announced on September 16, 2026 up to $600 million in a multi-year transformation of its U.S. operations, with a major share of that investment going toward doubling its manufacturing footprint in Wilson, North Carolina — the site of what will become Reckitt’s largest OTC manufacturing facility in the U.S. Jérôme Lemaire, President, Reckitt […]

Novo Nordisk and Anthropic Announce Collaboration to Advance Drug Discovery With Claude

Novo Nordisk and Anthropic announced a collaboration on September 16, 2026 aimed at helping Novo accelerate the development of new medicines and advance AI-driven software development. The companies will jointly address key drug discovery challenges identified by scientists and computational teams at Novo, developing targeted solutions for specific scientific challenges and workflows to support biological […]

Merck Launches “Your Hive of Whole Health” to Support Whole-Person Care for People Living With HIV

Merck, known as MSD outside the U.S. and Canada, launched Your Hive of Whole Health on September 18, 2026 — a multi-year educational program designed to help people living with HIV build personalized networks of support addressing their physical, mental, emotional, and social well-being. The initiative was unveiled at the 2026 U.S. Conference on HIV/AIDS […]

OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA’s Project Orbis Invitation for OST-HER2

OS Therapies, Inc., a Rockville, Maryland- and New York-based clinical-stage oncology company, announced on September 17, 2026 that it has achieved incremental alignment with the FDA on the adaptive design for the pending Phase 3 trial of OST-HER2 — its lead gene-edited, Listeria-based immunotherapy — in fully-resected, pulmonary metastatic osteosarcoma, matching the design already agreed […]

People on the Move: Dr. Jonathan Burke Selected as Director of the National Institute of Dental and Craniofacial Research

Jonathan E. Burke, D.M.D., has been selected to serve as Director of the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH), effective September 20, 2026. “Dr. Burke has spent his career at the intersection of surgical excellence and patient care and is a leader in craniofacial trauma and […]

Frederick’s Bio Networking Happy Hour Draws Scientists, Economic-Development Leaders to Matan at Riverside

Scientists, industry professionals, economic-development leaders, and community partners gathered September 9, at Matan at Riverside for the Bio Networking Happy Hour, an evening focused on connecting people across Frederick’s life sciences and technology ecosystem. The event was hosted by Matan Companies and sponsored by the City of Frederick Department of Economic Development and the Frederick […]

People on the Move: Rachel Chiaverelli Joins GSK as Executive Director, Oncology Early Translational Biomarkers

Rachel Chiaverelli, PhD, has joined GSK as Executive Director, Oncology Early Translational Biomarkers, after nearly four years at Daiichi Sankyo. “This new chapter in my career at GSK is particularly meaningful as I am returning to the place that was pivotal in driving my passion for translational medicine early in my career,” Chiaverelli said. “I […]